STRICTLY CONFIDENTIAL
Back
thesis
THE CORE THESIS
Not a hardware company.
The wearable industry spent a decade building better sensors. OIMUS is the first to build what comes after the sensor: a closed-loop biological operating system that senses, learns, and acts — automatically, individually, in real time.
KEY FIGURES
STRATEGIC CAPITAL
Tailord structure
CONDITIONS
235
PRV PATENTS
25
SUB: GROSS MARGIN
97%
ONE VHP DEAL
$78M ARR
01 - THE OPPORTUNITY
Every Wearable Measures.
None Act.
WHAT EXISTS TODAY
1.1B wearable users — zero autonomous orchestration
1–3 signals, population-norm algorithms
Category leaders: multi-billion valuations · no orchestration, no stimulation
WHAT OIMUS CHANGES
32 BioResponders & Sensors — bilateral, simultaneous
400+ Biomarkers · 235 conditions addressed
oiBOS: individual calibration — you vs you, never norms
02 - THE PRODUCTS
BioBuds
A nine-layer in-ear biological operating system, worn 6–8 hours daily. The hardware is the entry point; the architecture is the asset. Three simultaneous nerve pathways — accessed only through the ear. No wrist, ring, or patch device can replicate this.
BILATERAL NEURAL CHANNELS
32
NERVE PATHWAYS
3
LAUNCH PRICE
€399
HW GROSS MARGIN
76%
oiBOS
Beneath the hardware sits oiBOS (OIMUS Biological Operating System) — the adaptive closed-loop intelligence layer that no competitor has. oiBOS does not produce a dashboard. It produces an action.
SENSE → LEARN → INTERPRET → ORCHESTRATE → ACT
Beneath the hardware sits oiBOS (OIMUS Biological Operating System) — the adaptive closed-loop intelligence layer that no competitor has. oiBOS does not produce a dashboard. It produces an action.
03 - THE MOAT
Four Layers. One Biological Intelligence Platform.
Every existing daily wearable in the category — from fitness trackers to premium audio devices — measures, informs, and returns the burden to the user. None act. None adapt. None are calibrated to the individual.
OIMUS BioBud
Three nerve pathways
1
CN X
Primary pathway for parasympathetic regulation, recovery, and stress adaptation.
2
CN V3 (Trigeminal Nerve)
Sensory gateway influencing perception, autonomic signaling, and neurophysiological feedback.
3
C2-C3
Supportive pathways connecting the neck, posture, and autonomic regulation.
BioBud is the interface.
The physical interface between biology and intelligence.
Built on clinically established neuromodulation pathways and designed for continuous everyday wear. Already worn. Already accepted. Already scalable.
oiBOS is the intelligence.
The world’s first biological operating system.
Continuously reads biology, interprets change, and orchestrates personalized responses in real time.
NeuralProfile is the memory.
The longer BioBuds is worn, the better it gets — for you, by you.
30–90-day individual calibration, irreversible once established. 500,000 longitudinal biological models cannot be replicated through capital alone.
TrueCoreID is the trust.
Your biology becomes your identity.
Never stored, shared, or forged. Verified only through your own physiology. The foundation for trusted health data, secure AI, and human verification.
Together, they create a platform no single technology can replicate.
04 - MARKET
$550B+ Combined TAM
Four converging verticals, all reaching inflection in 2026–2028 as EU AI Act, PSD3, NIS2, MENA Sovereign ID, and eIDAS 2.0 pull demand simultaneously.
05 - REVENUE MODEL
Five Streams. One Hardware Sale.
Subscription delivers at 97% margin. One enterprise VHP deal can return the entire raise at signing.
3YR GM · 500K UNITS
€985M
PATH TO $1B
2–3M users
ONE VHP DEAL AT SIGNING
€78M ARR
06 - CLINICAL PATHWAY
Three Phases. Day 1 Without Clearance.
CE Class I — Wellness
Active from Day 1. No clearance required. This is the launch classification under which BioBuds ship.
CE Class IIa — Migraine / PTSD
Insurance reimbursement pathway. Clinical pilot n=50 — an R1 funding deliverable, targeted Q1 2027.
Prescription-Equivalent & Pharma REL
Prescription-equivalent pathways and pharmaceutical REL partnerships — the long-term clinical and research expansion.
07 — TEAM & IP
25 Patents. Filed Before Capital.
Carl-Fredrik Brundin
Founder & Systems Architect, leads MENA/Asia personally.
Jacqueline Brundin
Co-Founder, IP - registered inventor on all 25 patents.
Henrik Lindmark
Co-Founder & CPO (leads product)
Dr. Rickard Hultgren
Medical Advisor · Clinical Evidence Architect.
Kim Born
leads Nordic commercial relations.
25 PRV patents filed — all before external capital. PCT filing in progress. IP held in family trust above all operating entities (SE/EE/MY/UAE-ADGM).
08 - THE ASK
Strategic capital -Pure Equity
€80–150M Target Pre-money Valuation
Pre-money valuation reflects the 25-patent portfolio filed pre-capital, early sovereign-level VHP traction, and the multi-vertical infrastructure opportunity across a €550B+ combined TAM.
This round delivers
BioBuds production-intent hardware
oiBOS platform v1 · VHP sovereign pilots
100K Founding Members first cohort
NeuralProfile database seeded
Clinical pilot n=50 · clinical documentation package
Why now
AI has reached biology — enabling a new category
Legislation and digital identity are converging (2026–2028)
Human verification is becoming critical infrastructure
Wearables are shifting from measurement to autonomous action
Prevention and longevity are becoming economic priorities
Technology, IP, and market timing have finally aligned
